WBR0881
| Author | [[PageAuthor::Rim Halaby, M.D. [1]]] |
|---|---|
| Exam Type | ExamType::USMLE Step 1 |
| Main Category | MainCategory::Pharmacology |
| Sub Category | SubCategory::Hematology |
| Prompt | [[Prompt::A new drug is being developed for the treatment of intermittent claudication. One of the main studied mechanisms of action of this drug is the inhibition of phosphodiesterase III leading to arterial vasodilation to improve blood flow to ischemic areas and decrease the symptoms of claudication. What would you expect drugs with a similar mechanism of action to have as added benefit?]] |
| Answer A | AnswerA::Slowing of atherosclerotic vessel changes |
| Answer A Explanation | AnswerAExp:: |
| Answer B | AnswerB::Inhibition of platelet aggregation |
| Answer B Explanation | AnswerBExp:: |
| Answer C | AnswerC::Conversion of plasminogen to plasmin |
| Answer C Explanation | AnswerCExp:: |
| Answer D | AnswerD::Dulling of inflammatory response |
| Answer D Explanation | AnswerDExp:: |
| Answer E | AnswerE::Curing erectile dysfunction |
| Answer E Explanation | AnswerEExp:: |
| Right Answer | RightAnswer::B |
| Explanation | [[Explanation:: Educational Objective: |
| Approved | Approved::No |
| Keyword | WBRKeyword::Dipyridamole, WBRKeyword::cilostazol, WBRKeyword::PDE3 inhibitors |
| Linked Question | Linked:: |
| Order in Linked Questions | LinkedOrder:: |